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Abstract 
Von Hippel-Lindau disease is a highly penetrant autosomal genetic disorder caused by a germline mutation in the tumour suppressor 
gene, manifesting with the formation of various tumours, including neuroendocrine tumours of the pancreas. The incidence of the latter 
is not very high, varying from 5% to 18%. To compare, haemangioblastomas and clear cell renal carcinoma are present in 70% of von 
Hippel-Lindau patients and are considered the main prognostic factors, with renal cancer being the most common cause of death. However, 
pancreatic neuroendocrine tumours should not be neglected, considering their malignant potential (different to sporadic cases), natural 
history, and treatment protocol. This paper aims to review the literature on the epidemiology, natural history, treatment, and surveillance 
of individuals affected by pancreatic neuroendocrine tumours in von Hippel-Lindau disease. (Endokrynol Pol 2020; 71 (3): 256–259)
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Introduction 
Von Hippel-Lindau disease (VHL) is a highly penetrant 
autosomal genetic disorder caused by a germline muta-
tion in the VHL tumour suppressor gene located on the 
short arm of chromosome 3. The disease presents with 
the formation of tumours (both benign and malignant) 
and cysts in various organs. The incidence of pancreatic 
neuroendocrine tumours (PNETs) in VHL disease is 
not very high, varying from 5 to 18% depending on 
the study. To compare, haemangioblastomas and clear 
cell renal carcinoma (RCC) are present in 70% of VHL 
patients and are considered as the main prognostic fac-
tors, with renal cancer being the most common cause 
of death [1–5]. However, considering the malignant 
potential of PNETs and improving life expectance in 
VHL, it is important to screen VHL patients for PNETs 
in order to detect them at an early stage [6, 7]. The 
paper reviews the literature on the incidence, clinical 
presentation, and treatment of PNETs in VHL disease. 
Pancreatic lesions in von Hippel-Lindau 
disease
In total, pancreatic lesions related to VHL are common, 
with prevalence ranging from 17 to 87% depending 
on the study [1, 4, 8–10]. Interestingly, in a group of 
52 VHL patients evaluated by Hough, there were six 
people (12%) in whom pancreatic involvement was the 
only abdominal manifestation of the disease [9]. Fur-
thermore, in the study by Hammel, VHL disease was 
diagnosed accidently in 6% of patients during imaging 
examinations performed for unrelated reason [8]. 
Pancreatic lesions found in VHL disease are a het-
erogenous group. As well as PNETs, pancreatic true 
cysts and serous cystadenomas have been described [4]. 
Furthermore, mixed serous neuroendocrine neoplasms 
(MSNN) with the components of both serous cyst ad-
enoma and of neuroendocrine tumour can develop [11]. 
Also a few cases of haemangioblastomas, renal cancer 
metastases, and a case pancreatic adenocarcinoma have 
been stated in VHL [8, 12, 13]. 
Of all the lesions, cysts are the most common and 
are found in 17–56% of the patients during routine 
screening [1, 14, 15]. At autopsy, the percentage of true 
cysts in VHL patients is even higher, reaching 72% 
[14, 16]. Typically, the cysts and serous cystadenomas 
are benign, asymptomatic, and are detected during 
routine screening of VHL family members. However, 
they tend to grow in approximately 50% of patients. In 
20%, they may eventually compress pancreatic duct or 
neighbouring organs [8, 9]. In the course of pancreatic 
cyst growth, the development of diabetes mellitus and 
a case of acute pancreatitis have also been documented 
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Natural history of pancreatic neuroendocrine 
tumours in von Hippel-Lindau disease
Distant metastases are found in 60–90% of sporadic 
PNETs, whereas in VHL the incidence of metastases 
is lower and estimated at 11–20%. The question arises 
whether this is due to the higher malignant potential of 
sporadic PNETs or is a consequence of regular imaging 
studies of the abdomen performed in VHL and thus 
earlier tumour recognition. Yamasaki points out that 
sporadic non-functioning PNETs typically grow up to 
5 cm in diameter until they are detected, because there 
are no previous alert hormonal symptoms [26]. In the 
study by de Mestier the median Ki index for PNETs in 
VHL and in sporadic cases was 3% and 4%, respec-
tively, and this difference was not statistically signifi-
cant (p = 0.95). Furthermore, lymph node metastases 
were detected in 43% and 30%, respectively (p = 0.45). 
Generally, VHL-related PNETs can be classified to G1 
or G2 according to WHO grading [23]. However, a case 
of G3 PNET was described by Japanese authors with 
Ki67 index = 40%. At the diagnosis, the tumour size 
was 4 cm and liver metastases were already detected 
[27]. In the observation study performed by de Mestier, 
VHL-related PNETs smaller than 15 mm in diameter did 
not progress during 10-year follow-up [23]. According 
to Blansfield, in VHL, the exon 3 mutation determines 
a more aggressive course and metastases development. 
Also, metastases development is more likely in tumours 
larger than 3 cm in diameter [3]. Mixed serous neuro-
endocrine neoplasms seem to have higher malignant 
potential than PNETs alone [11]. Generally, PNETs are 
regarded as a rare cause of death in VHL [3]. Renal clear 
cell cancer giving metastases in approximately 45% of 
VHL patients is the commonest cause of morbidity in 
VHL [14, 28, 29]. 
Imaging studies of pancreatic neuroendocrine 
tumours in von Hippel-Lindau disease
Pancreatic neuroendocrine tumours, being richly vas-
cularised, present as strongly enhanced tumours in 
dynamic computer tomography with iodine contrast [9, 
10, 18]. On MRI, they are hypointense in T1 images and 
hyperintense in T2 scans. Both CT and MR examination 
seem comparable in terms of detecting primary pan-
creatic lesion. Yet, MRI is considered more effective in 
finding metastases in the liver [10, 21]. Typically, PNETs 
are well circumscribed and encapsulated [1].
Endoscopic ultrasound exploration is a very sensi-
tive method enabling pancreatic tumour detection. 
Furthermore, there is a possibility of performing tu-
mour biopsy during the examination thus enabling 
establishment of the NET diagnosis [24]. 
[8, 17]. Cysts in VHL disease, as in many other genetic 
syndromes, are often multiple [8]. Thus, detection of 
several pancreatic cysts in an imaging examination 
should always raise suspicion of VHL or another 
genetic syndrome. According to Hough, the presence 
of a single pancreatic cyst in a patient with positive 
VHL family history makes the diagnosis of VHL very 
probable, whereas multiple cysts make the diagnosis 
certain [9]. 
Epidemiology of pancreatic neuroendocrine 
tumours in von Hippel-Lindau disease
In the general population, PNETs constitute ap-
proximately 5% of all pancreatic neoplasms [18]. 
Their incidence in VHL disease is estimated at 5–18%. 
However, taking all PNETs together, the possibility of 
PNET being a part of VHL is evaluated at less than 
0.5% [19]. Pancreatic neuroendocrine tumours in VHL 
can be located throughout the pancreas [20]. They are 
often multiple and — typically — non-functioning [4, 
14, 19, 20, 21]. The mean detection age is lower than 
in sporadic cases. According to available reports, the 
youngest age at PNET diagnosis was 12 years [22]. 
In the study by de Mestier the mean age for VHL 
was 35 years and for sporadic cases — 58 years [23]. 
Similar results were obtained by Blansfield and by 
Erlic. The latter reported that mean age of recogni-
tion of sporadic and syndromic PNETs was 57 and 37 
years, respectively. The data on patient sex in PNET 
differ depending on the study. In the study by Eric, 
in VHL — women were more commonly affected by 
the disease than in sporadic cases (p = 0.01). Similarly, 
Hammel reported that women accounted for 66% 
of all VHL-related PNETs. However, in the study by 
Blansfield the male to female ratio was 1:1.1 (51 cases 
vs. 57 cases) [3, 8, 19]. 
Histopathology of pancreatic neuroendocrine 
tumours in von Hippel-Lindau disease
All PNETs, both sporadic and VHL-related, have ma-
lignant potential. Histopathologically, they should be 
evaluated according to the World Health Organisation 
2017 classification (a three-degree proliferation-based 
grading system with evaluation of Ki-67 index) [24]. 
The tumours are formed from pancreatic islet cells. In 
VHL disease, PNETs do not present evident hormonal 
activity [1]. However, in immunochemistry they are 
positive for chromogranin A and synaptophysin. 
They can also be positive for somatostatin, pancreatic 
polypeptide, and inhibin. Interestingly, in VHL, in 
contrast to many sporadic cases, they are not positive 
for gastrin [4, 25]. 
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Radioisotope diagnostic examinations are the most 
sensitive methods used in evaluation of NETs, includ-
ing PNETs. Somatostatin scintigraphy is characterised 
by approximately 80% sensitivity. It has the highest af-
finity to somatostatin receptors type 2 (SSTR2), which 
are present in PNETs. A less available but even more 
sensitive and specific method is Ga-68 somatostatin 
receptor PET/CT. Apart from visualising PNETs, Ga-68 
somatostatin receptor PET/CT can also be useful in 
VHL in detecting coexisting pheochromocytoma or 
neuroblastoma [30, 31]. 
Fluorodeoxyglucose-positron emission tomography 
(PET-FDG) can be particularly helpful in finding PNETs 
smaller than 1 cm in diameter or in visualising small 
hepatic metastases that cannot yet be seen in classic 
contrast-enhanced CT scans. Added to this, in certain 
situations, PET-FDG, unlike classic CT, may help to 
differentiate serous pancreatic adenomas from PNETs, 
thus helping to decide whether to operate the patient 
or not [10, 32, 33]. 
Treatment of pancreatic neuroendocrine 
tumours in von Hippel-Lindau disease
Generally, sporadic non-secreting neuroendocrine tu-
mours of the pancreas should be removed when they 
are more than 20 mm in diameter. Smaller tumours can 
be observed if they have not got radiological or histo-
pathological features of malignancy [21, 24]. The data on 
PNET treatment in VHL are limited and based only on 
retrospective analysis. Prospective validated trials are 
missing. Generally, surgery should be recommended 
more carefully because the tumours are often multiple, 
and the patient is affected by more serious other organs’ 
lesions related to VHL. The patient’s general life expec-
tancy has to be taken into consideration as well as the 
effect of pancreatic tumour removal on his/her survival. 
On the one hand, tumour removal decreases the risk 
of the metastases; on the other hand, the surgery is 
related to certain complications. Possible complications 
related to PNET removal are pancreatic fistulas – their 
risk is higher in the case of VHL-related than in sporadic 
PNETs. Furthermore, perioperative infections are com-
mon [3, 21, 23]. The development of diabetes mellitus 
or loss of pancreatic exocrine function is also possible. 
Libutti et al. proposed tumour removal in the following 
situations:  neoplasm diameter > 30 mm (20 mm — if 
the tumour is located in the pancreatic head), during 
abdominal surgery for an unrelated reason, or if the 
tumour is symptomatic (despite its size) [15]. Accord-
ing to Blansfield, there are three major factors that 
determine the risk of metastases: tumour size, exon 
3 mutation, and mean doubling time. Thus, following 
Blansfield, in patients with primary lesion smaller than 
3 cm, without exon 3 mutation, and with doubling time 
shorter than 500 days a non-operative approach seems 
more reasonable with control image study repeated 
every two or three years. In patients who have one of 
the above factors, observation is also recommended 
but the imaging study should be repeated more 
frequently — every six months. Only patients who 
meet two or three criteria should be qualified for the 
surgery because they are at higher risk of developing 
metastases [3]. Treatment with somatostatin analogues 
is well documented in non-secreting PNETs in tumour 
stabilisation [24, 34]. Promising results were obtained 
in a case of multifocal PNETs in VHL where six-month 
therapy with lanreotide significantly diminished the 
size of the tumours [35]. In advanced disease, as in 
sporadic PNETs, treatment includes peptide receptor 
radioligand therapy (PRRT), chemotherapy, and mo-
lecularly targeted therapy [24]. In patients with VHL, 
who are affected at the same time by PNET and other 
VHL-related tumours, (pheochromocytoma, RCC, 
haemangioblastoma) sunitinib therapy led to mass 
reduction in all tumor types [36]. 
Follow-up
The surveillance schedule in VHL includes, among oth-
ers, searching for typical abdominal lesions. Typically, 
the image investigation of the abdomen begins in the 
age of eight years with annual ultrasound. Starting from 
the age of 16 years, abdominal MR once every two years 
is recommended [37]. 
Conclusion
Pancreatic neuroendocrine tumours in VHL disease 
are not very common, and thus there are few data on 
their management. Further studies are necessary in 
order to implement the ideal treatment schedule and 
surveillance algorithm. 
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